Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Deepankar Chakroborty

Showing results (1-10 of 13) with videos related to

Pageof 2
Sort By:
Iscience|January 22, 2026
Database of recurrent mutations, an unbiased web resource to browse recurrent mutations in cancersDeepankar Chakroborty, Katri Vaparanta, Bishwa Ghimire, et al.
BMC Cardiovascular Disorders|October 22, 2018
Receptor tyrosine kinase profiling of ischemic heart identifies ROR1 as a potential therapeutic targetJuho Heliste, Anne Jokilammi, Ilkka Paatero, et al.
Scientific Reports|November 10, 2018
Different responses of colorectal cancer cells to alternative sequences of cetuximab and oxaliplatinElli Narvi, Katri Vaparanta, Anna Karrila, et al.
Oncogene|May 28, 2024
Trans-activating mutations of the pseudokinase ERBB3Marika K A Koivu, Deepankar Chakroborty, Tomi T Airenne, et al.
Molecular Cancer Therapeutics|December 16, 2020
Identification of Predictive <i>ERBB</i> Mutations by Leveraging Publicly Available Cell Line DatabasesMarika K A Koivu, Deepankar Chakroborty, Mahlet Z Tamirat, et al.
BMC Cancer|July 25, 2019
L1TD1 - a prognostic marker for colon cancerDeepankar Chakroborty, Maheswara Reddy Emani, Riku Klén, et al.
Stem Cell Reports|February 24, 2015
The L1TD1 protein interactome reveals the importance of post-transcriptional regulation in human pluripotencyMaheswara Reddy Emani, Elisa Närvä, Aki Stubb, et al.
The Journal of Biological Chemistry|April 7, 2019
An unbiased <i>in vitro</i> screen for activating epidermal growth factor receptor mutationsDeepankar Chakroborty, Kari J Kurppa, Ilkka Paatero, et al.
EMBO Molecular Medicine|June 17, 2024
DUSP6 inhibition overcomes neuregulin/HER3-driven therapy tolerance in HER2+ breast cancerMajid Momeny, Mari Tienhaara, Mukund Sharma, et al.
Cancer Research Communications|March 2, 2023
An Unbiased Functional Genetics Screen Identifies Rare Activating ERBB4 MutationsDeepankar Chakroborty, Veera K Ojala, Anna M Knittle, et al.
Pageof 2

Showing results (1-10 of 13) with videos related to

Sort By:
Pageof 2
Iscience|January 22, 2026
Database of recurrent mutations, an unbiased web resource to browse recurrent mutations in cancersDeepankar Chakroborty, Katri Vaparanta, Bishwa Ghimire, et al.
BMC Cardiovascular Disorders|October 22, 2018
Receptor tyrosine kinase profiling of ischemic heart identifies ROR1 as a potential therapeutic targetJuho Heliste, Anne Jokilammi, Ilkka Paatero, et al.
Scientific Reports|November 10, 2018
Different responses of colorectal cancer cells to alternative sequences of cetuximab and oxaliplatinElli Narvi, Katri Vaparanta, Anna Karrila, et al.
Oncogene|May 28, 2024
Trans-activating mutations of the pseudokinase ERBB3Marika K A Koivu, Deepankar Chakroborty, Tomi T Airenne, et al.
Molecular Cancer Therapeutics|December 16, 2020
Identification of Predictive <i>ERBB</i> Mutations by Leveraging Publicly Available Cell Line DatabasesMarika K A Koivu, Deepankar Chakroborty, Mahlet Z Tamirat, et al.
BMC Cancer|July 25, 2019
L1TD1 - a prognostic marker for colon cancerDeepankar Chakroborty, Maheswara Reddy Emani, Riku Klén, et al.
Stem Cell Reports|February 24, 2015
The L1TD1 protein interactome reveals the importance of post-transcriptional regulation in human pluripotencyMaheswara Reddy Emani, Elisa Närvä, Aki Stubb, et al.
The Journal of Biological Chemistry|April 7, 2019
An unbiased <i>in vitro</i> screen for activating epidermal growth factor receptor mutationsDeepankar Chakroborty, Kari J Kurppa, Ilkka Paatero, et al.
EMBO Molecular Medicine|June 17, 2024
DUSP6 inhibition overcomes neuregulin/HER3-driven therapy tolerance in HER2+ breast cancerMajid Momeny, Mari Tienhaara, Mukund Sharma, et al.
Cancer Research Communications|March 2, 2023
An Unbiased Functional Genetics Screen Identifies Rare Activating ERBB4 MutationsDeepankar Chakroborty, Veera K Ojala, Anna M Knittle, et al.
Pageof 2